TABLE 1B.
Patient population characteristics for the six training sets.
| Trial 1 (n = 102) | Trial 2 (n = 102) | Trial 3 (n = 102) | Trial 4 (n = 102) | Trial 5 (n = 102) | Trial 6 (n = 102) | |
| Sex (female, %) | 90% | 91% | 91% | 93% | 90% | 89% |
| Age (mean ± SD) | 44 ± 13 | 41 ± 12 | 41 ± 12 | 41 ± 12 | 41 ± 14 | 43 ± 13 |
| SLE duration (mean ± SD) | 7 ± 8 | 7 ± 8 | 7 ± 7 | 8 ± 8 | 7 ± 8 | 7 ± 8 |
| SLEDAI-2K (mean ± SD) | 2 ± 2 | 2 ± 2 | 2 ± 2 | 2 ± 2 | 2 ± 2 | 2 ± 2 |
| SDI (mean ± SD) | 1 ± 1.2 | 0.8 ± 1 | 0.8 ± 1 | 0.8 ± 1 | 0.9 ± 1.1 | 0.9 ± 1.1 |
Sex, age and SLE clinical variables are described for the population included in each training set of each trial. SLEDAI = Systemic Lupus Erythematosus Disease Activity Index 2000. SDI = Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.